Sign In
Buy TOVX
$0.210
-0.0001 (-0.0476%)
At Close: Jul 31, 2026
Theriva Biologics, Inc. (TOVX) Q3 2023 Earnings Call Transcript
12:51pm, Friday, 17'th Nov 2023
Theriva Biologics, Inc. (NYSE:TOVX ) Q3 2023 Results Conference Call November 13, 2023 8:30 AM ET Company Participants Steve Shallcross - Chief Executive and CFO Dr. Manel Cascalló - General Director
Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results
08:00am, Monday, 13'th Nov 2023
- VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma remains on track to complete enrollment in the first half of 2024; mult
Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial Results
04:05pm, Monday, 06'th Nov 2023
ROCKVILLE, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in
Theriva™ Biologics to Participate in the BIO-Europe Conference
04:15pm, Thursday, 02'nd Nov 2023
ROCKVILLE, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases
- Theriva signs exclusive option to license intellectual property from Sant Joan de Déu-Barcelona Children's Hospital (SJD) to explore the therapeutic potential of VCN-01 in combination with topoisom
-Results show enhanced patient survival, correlating with VCN-01 mediated increases in the CPS score, a key determinant of outcomes with anti-PD-(L)1 checkpoint inhibitor therapies-
-Results from investigator-sponsored study in collaboration with the Institut Catala d'Oncologia (ICO) show enhanced patient survival, correlating with VCN-01 induced upregulation of PD(L)-1-
Theriva Biologics to Participate in the Emerging Growth Conference
08:00am, Thursday, 28'th Sep 2023
ROCKVILLE, Md., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases i
Theriva Biologics, Inc. (TOVX) Q2 2023 Earnings Call Transcript
01:52pm, Saturday, 12'th Aug 2023
Theriva Biologics, Inc. (NYSE:TOVX ) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Company Participants Chris Calabrese - IR, LifeSci Advisors Steven Shallcross - Chief Executive and CFO D
Theriva Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2023 Operational Highlights and Financial Results
04:05pm, Tuesday, 01'st Aug 2023
ROCKVILLE, Md., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in
Theriva Biologics jumps on US FDA approval for pancreatic cancer treatment
08:51am, Wednesday, 28'th Jun 2023
Theriva Biologics Inc saw its shares surge over 70% higher in after-hours US trading following news that its lead clinical candidate, VCN-01, has been granted orphan drug designation by the US Food a
Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results
08:00am, Thursday, 04'th May 2023
ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in
Conference call to be held on Thursday, March 30 at 8:30 a.m. ET Conference call to be held on Thursday, March 30 at 8:30 a.m. ET
ROCKVILLE, Md., March 20, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases i
Theriva Biologics to Participate in Upcoming Investor Conferences
08:00am, Thursday, 01'st Dec 2022
ROCKVILLE, Md., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed t
